The Clinical Research Of The Correlation Between VWF And ACS And The Therapeutical Effect Of Different Doses Of Rosuvastain

The Clinical Research of The Correlation between VWF and ACS and The Therapeutical Effect of Different doses of RosuvastatinObjective:Despite of receiving reperfusion therapy and optimal medication, abnormal myocardial perfusion can be seen in patients with acute coronary syndrome (ACS) which expands the infarction area, decreases the left ventricular ejection fraction, and reduces the livability. The activation of endothelial cell and the releasing of inflammation factors play an important role in the occurrence and process of ACS. Von Willebrand factor (VWF) is a very specific inflammation factor reflecting acute endothelial injuries. A number of studies showed that increased concentration of plasma VWF was an independent risk factor of unfavorable prognosis in patients with ACS. Statins is the base drug in the treatment of coronary heart disease. Besides of lowering cholesterol, statins stabilize plaque, improve endothelial function, anti-inflammation, anti-oxidant etc. This study aims to:1.observe various plasma concentration of VWF in health adult, patients with stable angina and ACS to evaluate the correlation between VWF and ACS; 2.observe the inhibition of VWF by different doses of Rosuvastatin to seek a new and potential valued treatment of ACS.Methods:Selected 110 subjects. They were divided into four groups:20 healthy adults (control group); 30 patients with stable angina (SA group); 30 patients presenting with ACS (ACS group); 30 patients with ACS treated by high-dose Rosuvastatin (H group). Patients in ACS group and H group had plasma samples taken at admission and one week later. The control group and UA group had plasma samples taken at admission. Plasma concentration of von Willebrand factor was measured by enzyme-like immunosorbent assay (ELISA). Results:1. There was no significant difference of the VWF plasma concentration between SA group and the control group (P>0.05),the ACS group and the H group (P>0.05); VWF plasma concentration is significantly higher of the patients in the ACS group and the H group than that of the patients in the SA group and the control group (P<0.05).3. There is no significant change of VWF plasma concentration one week later in ACS group (P<0.05). But significant depression of the VWF plasma concentration was observed in the H group one week later (P<0.05).Conclusions:1. Plasma VWF concentration is a weak predictor of coronary heart disease in the general population;2. The increased VWF plasma concentration is a marker of the occurrence of ACS; it may play an important role in the process of ACS;3. High dose of Rosuvastatin can decrease VWF plasma concentration in patients with ACS, has endothelial protective effect. And this is independent of its lipid-lowering effects.